GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent- N-arylbenzamide LRRK2 kinase inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 17, 2012, Pages 5625-5629

  Reith, Alastair D ^a   Bamborough, Paul ^a   Jandu, Karamjit ^a,e,f   Andreotti, Daniele ^a,e,g   Mensah, Lucy ^a   Dossang, Pamela ^a,h   Choi, Hwan Geun ^b,c   Deng, Xianming ^b,c   Zhang, Jinwei ^d   Alessi, Dario R ^d   Gray, Nathanael S ^b,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e GSK   (Italy)

^f BioFocus DPI   (United Kingdom)

^g Aptuit Inc   (United States)

^h Vernalis PLC   (United Kingdom)

Author keywords

Drug discovery; Kinase inhibitors; LRRK2; Parkinson's disease

Indexed keywords

BENZAMIDE DERIVATIVE; GSK 2578215A; LEUCINE RICH REPEAT KINASE 2; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; KIDNEY; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SPLEEN; WILD TYPE;

3T3 CELLS; ANIMALS; BRAIN; CELL LINE; DRUG DISCOVERY; HEK293 CELLS; HUMANS; MALE; MICE; MODELS, MOLECULAR; MUTATION; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84865149238     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.06.104     Document Type: Article

References (16)

1. P.N. Gandhi, S.G. Chen, and A.L. Wilson-Delfosse J. Neurosci. Res. 87 2009 1283
2. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, and C.M. Tanner Neurology 68 2007 384
3. V. Daniels, V. Baekelandt, and J.M. Taymans Neuro-Signals 19 2011 1
4. D.G. Healy, M. Falchi, S.S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C.P. Zabetian, S. Goldwurm, J.J. Ferreira, E. Tolosa, D.M. Kay, C. Klein, D.R. Williams, C. Marras, A.E. Lang, Z.K. Wszolek, J. Berciano, A.H. Schapira, T. Lynch, K.P. Bhatia, T. Gasser, A.J. Lees, and N.W. Wood Lancet Neurol. 7 2008 583
5. J.C. Dächsel, and M.J. Farrer Arch. Neurol. 67 2010 542
6. E. Greggio, and M.R. Cookson ASN Neuro 2009 1
7. A. Kumar, and M.R. Cookson Expert Rev. Mol. Med. 13 2011 e20
8. X. Deng, N. Dzamko, A. Prescott, P. Davies, Q. Liu, Q. Yang, J.D. Lee, M.P. Patricelli, T.K. Nomanbhoy, D.R. Alessi, and N.S. Gray Nat. Chem. Biol. 7 2011 203
9. N. Ramsden, J. Perrin, Z. Ren, B.D. Lee, N. Zinn, V.L. Dawson, D. Tam, M. Bova, M. Lang, G. Drewes, M. Bantscheff, F. Bard, T.M. Dawson, and C. Hopf ACS Chem. Biol. 1021 2011 6
10. Patent Application WO2011/038572.
11. Dai et al., in preparation.
12. R.J. Nichols, N. Dzamko, J.E. Hutti, L.C. Cantley, M. Deak, J. Moran, P. Bamborough, A.D. Reith, and D.R. Alessi Biochem. J. 424 2009 47
13. J. Zhang, X. Deng, H.G. Choi, D.R. Alessi, and N.S. Gray Bioorg. Med. Chem. Lett. 2012 1864 22
14. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, and P. Cohen Biochem. J. 408 2007 297
15. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D. Lockhart J. Nat. Biotechnol. 23 2005 329
16. N. Dzamko, M. Deak, F. Hentati, A.D. Reith, A.R. Prescott, D.R. Alessi, and R.J. Nichols Biochem. J. 430 2010 405